FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 257 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 20 years of Cancer Research UK: Celebrating our research nurses December 7, 2022 Exosomes May Help Tumors Evade Immune System September 7, 2018 SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests December 21, 2020 Load more HOT NEWS Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. How radiotherapy became a lifesaver – from X-rays to the proton... Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast...
